EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A

Lara V Graham iD, Russell B Foxall, Margaret Ashton-Key, Salim I Khakoo iD, Souraya Sayegh iD, Maria Leandro, Venkat R Reddy iD, Mark S Cragg iD, Matthew D Blunt iD

Clinical and Experimental Immunology · 2026

DOI: 10.1093/cei/uxag001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2026. Verfasst von Lara V Graham und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical and Experimental Sciences, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Rituximab, Antibody-Dependent Cell Cytotoxicity, B-Lymphocytes, NK Cell Lectin-Like Receptor Subfamily C. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: John Goldman Fellowship Follow-up, Blood Cancer UK, University of Southampton Cancer Immunology Talent Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoreactive B cells that remain in lymphatic tissue after anti-CD20 antibody therapy are considered a major contributing factor to relapse in patients with autoimmune diseases. Natural killer (NK) cells contribute to the depletion of autoreactive B cells by anti-CD20 antibodies via antibody-dependent cellular cytotoxicity (ADCC). However, the impact of germinal centre–associated signals CD40 ligand (CD40L) and interleukin-4 (IL-4) on ADCC was unknown. This study used a combination of flow cytometry, immunohistochemistry, and ex vivo functional assays using peripheral blood mononuclear cells to investigate how CD40L and IL-4 affect NK cell–B cell interactions. CD40L and IL-4 significantly upregulate human leukocyte antigen (HLA)-E and total HLA Class I expression on the surface of B cells from healthy donors, as well as patients with rheumatoid arthritis and systemic lupus erythematosus. The upregulation of HLA-E and total HLA functions to inhibit B-cell depletion by NK cell–mediated ADCC induced by rituximab via NKG2A and killer cell immunoglobulin-like receptors (KIR). Moreover, B cells that have differentiated through the germinal centre have higher expression of HLA-E and total HLA compared with naive B cells and are more resistant to depletion by rituximab. In accordance with this, blockade of NKG2A and inhibitory KIRs by monalizumab and lirilumab, respectively, increased antibody-dependent cellular cytotoxicity against autologous B cells in vitro. Overall, this study identifies a novel mechanism of resistance of B cells to NK cell cytotoxicity and indicates that blockade of the HLA-E:NKG2A and HLA:KIR checkpoint axes could be beneficial for improving B-cell depletion in patients with autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabAntibody-Dependent Cell CytotoxicityB-LymphocytesNK Cell Lectin-Like Receptor Subfamily CInterleukin-4Receptors, KIRLymph NodesHumansKiller Cells, NaturalHLA-E AntigensHistocompatibility Antigens Class IFemaleArthritis, RheumatoidLupus Erythematosus, SystemicAdultSignal TransductionMiddle AgedMale

Stichwörter der Autor:innen

antibodiesautoimmunitynatural killer cells

Substanzen

RituximabNK Cell Lectin-Like Receptor Subfamily CHLA-E AntigensHistocompatibility Antigens Class IInterleukin-4Receptors, KIRKLRC1 protein, humanIL4 protein, human

Autor:innen und Institutionen

  • School of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
  • School of Cancer Sciences, University of Southampton, Southampton, UK.
  • Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Deparment of Ageing, Rheumatology and Regenerative Medicine, UCL, London, UK.
  • Department of Rheumatology, University College London Hospital, London, UK.

ORCID-Profile: Lara V Graham, Salim I Khakoo, Souraya Sayegh, Venkat R Reddy, Mark S Cragg, Matthew D Blunt

Förderung

  • John Goldman Fellowship Follow-up
  • Blood Cancer UK
  • University of Southampton Cancer Immunology Talent Fund
  • MRC-CARP Fellowship
  • UK Research and Innovation, Medical Research Council
  • UCLH Biomedical Research Centre
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Graham, L. V., Foxall, R. B., Ashton-Key, M., Khakoo, S. I., Sayegh, S., Leandro, M., Reddy, V. R., Cragg, M. S., & Blunt, M. D. (2026). CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxag001

Vancouver

Graham LV, Foxall RB, Ashton-Key M, Khakoo SI, Sayegh S, Leandro M, et al. CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A. Clinical and Experimental Immunology. 2026. doi:10.1093/cei/uxag001

BibTeX
@article{Graham2026,
  author = {Graham, Lara V and Foxall, Russell B and Ashton-Key, Margaret and Khakoo, Salim I and Sayegh, Souraya and Leandro, Maria and Reddy, Venkat R and Cragg, Mark S and Blunt, Matthew D},
  title = {CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  doi = {10.1093/cei/uxag001}
}
Kostenlos starten →